Stock News

J.P. Morgan Downgrades Dynavax (DVAX); 6 Analysts Bullish Marshalls plc (LON:MSLH)

Among 8 analysts covering Marshalls PLC (LON:MSLH), 6 have Buy rating, 1 Sell and 1 Hold. Therefore 75% are positive. Marshalls PLC had 67 analyst reports since August 28, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Friday, August 26 by Peel Hunt. The firm has “Buy” rating by Peel Hunt given on Friday, December 9. Numis Securities maintained the shares of MSLH in report on Wednesday, May 10 with “Add” rating. Peel Hunt maintained it with “Buy” rating and GBX 415 target in Wednesday, May 10 report. Peel Hunt maintained it with “Buy” rating and GBX 355 target in Tuesday, July 5 report. The rating was maintained by Shore Capital with “Buy” on Thursday, October 19. Panmure Gordon maintained Marshalls plc (LON:MSLH) on Thursday, December 10 with “Buy” rating. The firm earned “Buy” rating on Wednesday, June 29 by Jefferies. On Friday, March 11 the stock rating was upgraded by Numis Securities to “Buy”. Peel Hunt maintained the shares of MSLH in report on Thursday, October 19 with “Buy” rating. See Marshalls plc (LON:MSLH) latest ratings:

10/01/2018 Broker: Numis Securities Rating: Add Old Target: GBX 500.00 New Target: GBX 500.00 Maintain
10/01/2018 Broker: Shore Capital Rating: Buy Maintain
10/01/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 490.00 New Target: GBX 490.00 Maintain
04/01/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 490.00 New Target: GBX 490.00 Maintain
06/12/2017 Broker: Peel Hunt Rating: Buy Old Target: GBX 490.00 New Target: GBX 490.00 Maintain
27/11/2017 Broker: Barclays Capital Rating: Underweight New Target: GBX 429.00 Initiates Starts
16/11/2017 Broker: Berenberg Rating: Buy Upgrade
26/10/2017 Broker: Shore Capital Rating: Buy Maintain
20/10/2017 Broker: Canaccord Genuity Rating: Hold Old Target: GBX 415.00 New Target: GBX 465.00 Reiteration
20/10/2017 Broker: Jefferies Rating: Buy Old Target: GBX 490.00 New Target: GBX 520.00 Maintain

Among 6 analysts covering Dynavax Technologies (NASDAQ:DVAX), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Dynavax Technologies has $48 highest and $700 lowest target. $26.57’s average target is 56.29% above currents $17 stock price. Dynavax Technologies had 20 analyst reports since August 12, 2015 according to SRatingsIntel. The rating was upgraded by J.P. Morgan on Monday, July 31 to “Buy”. As per Monday, July 31, the company rating was upgraded by RBC Capital Markets. The stock of Dynavax Technologies Corporation (NASDAQ:DVAX) earned “Hold” rating by RBC Capital Markets on Wednesday, July 26. RBC Capital Markets downgraded Dynavax Technologies Corporation (NASDAQ:DVAX) on Thursday, April 28 to “Sector Perform” rating. JP Morgan downgraded Dynavax Technologies Corporation (NASDAQ:DVAX) rating on Wednesday, April 27. JP Morgan has “Neutral” rating and $22 target. The firm earned “Hold” rating on Friday, July 21 by J.P. Morgan. Zacks upgraded it to “Hold” rating and $33 target in Wednesday, August 12 report. The stock has “Buy” rating by William Blair on Monday, August 7. Cantor Fitzgerald maintained the shares of DVAX in report on Wednesday, September 27 with “Buy” rating. RBC Capital Markets initiated the stock with “Outperform” rating in Monday, November 30 report.

The stock decreased 1.16% or $0.2 during the last trading session, reaching $17. About 577,342 shares traded. Dynavax Technologies Corporation (NASDAQ:DVAX) has declined 63.84% since February 14, 2017 and is downtrending. It has underperformed by 80.54% the S&P500.

Analysts await Dynavax Technologies Corporation (NASDAQ:DVAX) to report earnings on March, 12. They expect $-0.35 earnings per share, up 37.50% or $0.21 from last year’s $-0.56 per share. After $-0.38 actual earnings per share reported by Dynavax Technologies Corporation for the previous quarter, Wall Street now forecasts -7.89% EPS growth.

Since December 13, 2017, it had 0 insider buys, and 2 sales for $199,261 activity. Shares for $141,750 were sold by COFFMAN ROBERT on Wednesday, December 13. 3,092 shares valued at $57,511 were sold by Johnson David Louis on Thursday, January 4.

Investors sentiment decreased to 2.06 in Q3 2017. Its down 0.27, from 2.33 in 2017Q2. It worsened, as 13 investors sold Dynavax Technologies Corporation shares while 19 reduced holdings. 25 funds opened positions while 41 raised stakes. 41.91 million shares or 20.83% more from 34.68 million shares in 2017Q2 were reported. Vanguard Grp has invested 0% in Dynavax Technologies Corporation (NASDAQ:DVAX). Rock Springs L P reported 165,000 shares stake. Point72 Asset Mngmt L P invested in 1.11M shares. Baker Bros Lp holds 0.01% in Dynavax Technologies Corporation (NASDAQ:DVAX) or 75,000 shares. Prelude Mngmt Limited Liability Co invested in 0% or 2,500 shares. Rhumbline Advisers reported 70,673 shares. Rhenman Prtn Asset Mgmt reported 1.03% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX). Weiss Multi holds 0.16% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX) for 200,000 shares. Voya Invest Mgmt Llc reported 27,887 shares. Guggenheim Capital Limited Liability Corp holds 109,039 shares. Mhr Fund Mgmt Llc holds 44,499 shares or 0.04% of its portfolio. Manufacturers Life Insur The holds 47,992 shares. Howard Hughes Med Institute owns 21,355 shares. Art Advisors Ltd, a New York-based fund reported 237,102 shares. Natl Bank Of Ny Mellon Corporation accumulated 359,650 shares or 0% of the stock.

Dynavax Technologies Corporation, a clinical-stage immunotherapy company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. The company has market cap of $1.03 billion. The Company’s product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. It currently has negative earnings. The company's lead product candidates include HEPLISAV-B, an investigational adult hepatitis B vaccine, which is in Phase III clinical trials; and SD-101, an investigational cancer immunotherapeutic that is in Phase I/II studies.

The stock increased 1.43% or GBX 5.6 during the last trading session, reaching GBX 397.6. About 199,669 shares traded. Marshalls plc (LON:MSLH) has 0.00% since February 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Leave a Reply

Your email address will not be published. Required fields are marked *